Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Cepheid Unveils Third-Generation GeneXpert System at ADLM 2026

By LabMedica International staff writers
Posted on 27 Jul 2026

Cepheid  is unveiling the third generation of its GeneXpert molecular diagnostic system at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Scientific Meeting. More...

The company is presenting the new platform during a special event on Tuesday, July 28, highlighting its expanded capabilities for PCR-based testing.

The third-generation GeneXpert system is designed to broaden the range of molecular testing available on a single platform while retaining the simplicity, flexibility, and reliability of existing GeneXpert workflows. According to the company, the system supports laboratories seeking to consolidate different types of molecular testing that may otherwise require multiple instruments and processes.

At launch, the platform is designed to support Cepheid’s comprehensive menu of U.S. Food and Drug Administration-cleared Xpert tests. It introduces a fully integrated touchscreen interface, redesigned software, and a more intuitive user experience while maintaining the workflows currently used by GeneXpert customers.

The system is also being developed to support a new generation of Xpert tests and applications. Planned capabilities include high-plex panel testing, faster time to results, and additional sample-to-answer solutions that could extend to next-generation sequencing workflows.

Like the company’s existing GeneXpert systems, the new platform provides random-access testing, allowing laboratories to process samples as they arrive rather than waiting to assemble batches. This approach enables urgent samples to be prioritized while supporting rapid access to actionable results across different healthcare environments.

The first configuration scheduled for release is a compact four-module system, with shipments to U.S. customers expected to begin in the coming months. Cepheid is also developing higher-capacity GeneXpert configurations and new GeneXpert Infinity systems for laboratories with larger testing volumes. The systems remain in development and have not been reviewed by a regulatory authority for diagnostic use.

Cepheid’s unveiling forms part of Danaher’s broader presence at ADLM 2026. At booth 3237, visitors can explore technologies from Danaher operating companies including Beckman Coulter Diagnostics, Beckman Coulter Life Sciences, Cytiva, HemoCue, Leica Biosystems, Radiometer, and SCIEX, covering diagnostic and life sciences workflows from discovery through clinical delivery.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hematology Consumables
Bioblood Devices
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.